Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 3 patents granted in the last 365 days
Galecto Biotech AB operates within the Biotechnology & Pharmaceuticals technology area with a portfolio currently containing 2 pending office actions. These actions are distributed across 2 distinct examiners and 2 distinct art units. This distribution indicates that each pending matter is being handled by a different examiner in a separate art unit, requiring a diversified approach to prosecution.
The busiest examiner for the company is CREWS, JARET JAMES, who is responsible for 1 pending office action. The presence of 2 distinct art units suggests that the company's intellectual property spans multiple specialized examination groups within the Biotechnology & Pharmaceuticals sector.
With 2 distinct examiners involved, the prosecution strategy is not centralized under a single individual. Each of the 2 pending office actions represents a unique interaction point with the patent office, requiring coordination across different examination environments to ensure consistency.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting only | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| CREWS, JARET JAMES | 1 | 44.7% | +70.3% |
| BERRY, LAYLA D | 1 | 66.0% | +9.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17785295 | LARGE SCALE PROCESS | BERRY, LAYLA D | 99d overdue |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18259146 | NOVEL GALACTOSIDE INHIBITOR OF GALECTINS | CREWS, JARET JAMES | 103d overdue |
| Art Unit | Apps |
|---|---|
| 1691 | 1 |
| 1693 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18259146 | NOVEL GALACTOSIDE INHIBITOR OF GALECTINS | CREWS, JARET JAMES | 1691 | DP | Final Rejection | 103d overdue | Pending | Jun 23, 2023 |
| 17785295 | LARGE SCALE PROCESS | BERRY, LAYLA D | 1693 | §103§112 | Non-Final OA | 99d overdue | Pending | Jun 14, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial